La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Heritage Global a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Heritage Global..

Heritage Global (NASDAQ:HGBL) Azioni, Catena delle Opzioni

Heritage Global

Heritage Glb

Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.

UBS analyst Joshua Spector maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Sell and lowers the price target from $50 to $49.

News

Price Target

Analyst Ratings

UBS Maintains Sell on LyondellBasell Industries, Lowers Price Target to $49

UBS analyst Joshua Spector maintains Huntsman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>) with a Neutral and lowers the price target from $13 to $11.

UBS Maintains Neutral on Huntsman, Lowers Price Target to $11

A surprise 50% import tariff on copper announced by President Donald Trump on Tuesday sent the red metal into a frenzy, driving prices to a historic high of $5.90 per pound as investors rushed to price <a href="https://www.benzinga.com/markets/equities/25/07/46305321/copper-price-surges-trump-tariffs-stocks-july-2025">in potential supply constraints.</a>
U.S.-based copper stocks Freeport-McMoRan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NASDAQ">FCX</a>) and Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) stand to post outsized gains if copper prices continue climbing.
While the measure appeared unplanned, the short implementation timeline—expected before the end of July or early August—has made it increasingly likely that the 50% rate will take effect, according to Goldman Sachs analyst Eoin Dinsmore.
"We change our baseline to a 50% tariff on U.S. copper imports from 25% previously," Dinsmore said in a note Wednesday. 
<h2 class="wp-block-heading">What's Driving The Copper Price Surge?</h2>
The shock tariff announcement comes amid already tight global copper supplies. 
Goldman Sachs maintained its December 2025 London Metal Exchange (LME) copper forecast at $9,700 per metric ton, but said the odds of prices exceeding $10,000 in the third quarter have diminished.
Still, with global supply lagging demand and the U.S. set to experience a copper stock drawdown, prices are likely to remain elevated for months, according to the bank.
&#8220;We expect a further acceleration in shipments into the U.S. in the coming weeks,&#8221; Dinsmore said, as traders rush to import ahead of tariff implementation.
Steel and aluminum tariffs were also raised to 50% in June, with markets pricing in 80% of that move—providing a precedent for copper to follow a similar pricing trajectory.
Copper's 13% advance on Tuesday not only marked its largest single-day rally on record, but also lifted prices to fresh all-time highs, said LPL Financial's chief technical strategist Adam Turnquist. While the metal has since pared some gains, it still remains above key support at $5.22 per pound.
"The surging demand for U.S. copper ahead of the looming tariffs has pushed domestic prices to a +25% premium over copper trading at the London Metal Exchange (LME)," Turnquist said. 
At the same time, LME inventories have been significantly depleted, raising concerns about a global supply shortage outside the U.S.
He added that rising copper prices could significantly affect copper-intensive sectors such as building construction, equipment manufacturing, electric vehicles and electronic products. 
"The widespread use of copper might also fuel inflation concerns," Turnquist said.
<h2 class="wp-block-heading">Which Stocks Could Potentially Gain From Trump's Copper Shock?</h2>
Freeport is the top U.S. copper equity play and holds a nearly 9% weighting in the iShares Copper and Metals Mining ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICOP#NYSE">ICOP</a>).
Southern Copper Corp. could another key beneficiary, with the stock returning 10.1% year-to-date.
Globally, copper production is heavily concentrated in Latin American countries like Chile and Peru—home to some of the world's largest deposits. 
This puts additional focus on companies such as Grupo México S.A.B. de C.V (OTCPK: GMBXF)., the parent of Southern Copper, and BHP Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>), which has significant operations in Chile's Escondida mine, the world's largest copper mine.
Other global players include First Quantum Minerals Ltd, Antofagasta plc (OTCPK: ANFGF), focused on Chilean mining, and Evolution Mining Ltd. (OTCPK: CAHPF), an Australian company diversifying into copper alongside its core gold assets.
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/07/46306953/emerging-markets-etfs-inflows-iemg-vwo-2025">Wall Street Is On Fire—So Why Is This Wall Of Cash Moving Abroad?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Equities

Government

Large Cap

Macro Economic Events

Regulations

Sector ETFs

Economics

ETFs

ANFGF

CAHPF

GMBXF

ICOP

SCCO

Trump's 50% Copper Tariff Shocks Markets—These Stocks Are Winning Big

Shaquille O'Neal may have four championship rings and a Hall of Fame plaque, but he's not handing his son a basketball legacy without a warning label.
In his new <a href="https://www.netflix.com/title/81757187">Netflix series "Power Moves with Shaquille O'Neal</a>," the 53-year-old NBA legend sits down with his 25-year-old son Shareef —<a href="https://gleague.nba.com/player/1631202/shareef-o'neal"> a G League forward with NBA ambitions</a> — and delivers a gut-check most young athletes never hear from their superstar parents.
"Are you ready to live that life? Because if you want to be great, my man, you've gotta sacrifice everything," Shaq told his son. "I've lost a family trying to be great."
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
O'Neal didn't say it for the cameras — he meant it. And this wasn't the first time he's opened up about the personal cost of building an empire.
"The Big Podcast with Shaq" last year, he <a href="https://www.benzinga.com/personal-finance/24/11/41910797/nba-legend-shaq-urged-jason-kelce-not-to-make-his-same-mistakes-i-lost-my-whole-family-im-in-a-100000-square-foot-house-by-myself">spoke with retired NFL star Jason Kelce</a> about the fallout of his obsession with success.
"I made a lot of dumbass mistakes to where I lost my family and I didn't have anybody," Shaq said. "Lost my whole family. I'm in a 100,000-square-foot house by myself."
That kind of clarity didn't come from a post-game press conference — it came from hindsight.
Now, as his son prepares to try out for the Sacramento Kings, O'Neal admits he's hesitant to watch Shareef step into a spotlight that may never fully be his own.
"I don't want him to play because it will be unfortunate for him that they will compare him to me," he said. "Similar to what Bronny James is going through now. Unfair to him, and I don't really want him to go through that."
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
He continued, "What he doesn't realize about me is I was crazy. Basketball's the only thing I cared about. It did jeopardize our relationship a little bit, and I don't want him to ever have to live like that. Everything comes back to the O'Neal name."
For Shareef, that name is both a blessing and a bullhorn.
"My dad missed birthdays, games, you know, Christmas," he said. "I respect it now. I know when I was a kid, we always used to ask, is your dad going to be here? We kind of knew that, okay, he's playing basketball, he's busy."
Despite the weight of comparisons and expectations, Shareef isn't backing down.
"I'm going to try out for the team, and if they offer me a spot, then I've got a lot to think about. I don't really have a plan B."
Shaq, once obsessed with greatness, now <a href="https://www.benzinga.com/personal-finance/management/25/07/46236482/shaq-was-80000-in-the-hole-when-he-took-an-old-timers-advice-hired-a-small-beautiful-man-who-put-his-money-in-bonds-and-an-s-corp">seems more focused on legacy</a> — not just stats, but stability. What started as a father-son talk about basketball turned into something deeper: a lesson about limits, identity, and the real scoreboard that matters when the buzzer sounds.
Because it turns out, being great on the court can cost you everything off it — and Shaq's making sure his son understands the difference.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence. </a></li>
</ul>
Image: Shutterstock

Personal Finance

NBA Legend Shaq Tells His 25-Year-Old Son, 'My Man, You've Gotta Sacrifice Everything' To Be Great —'I've Lost A Family Trying To Be Great'

UBS analyst Joshua Spector maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Buy and lowers the price target from $107 to $101.

UBS Maintains Buy on Eastman Chemical, Lowers Price Target to $101

Circle Internet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) has become one of the most polarizing stocks on Wall Street since its blockbuster IPO. Analyst coverage reveals a striking divergence in opinions on the stock, reflecting the complex and uncertain outlook<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46294493/this-circle-internet-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-tuesday"> for the company. </a>
Bearish: On one end of the spectrum, bearish analysts cite concerns about overvaluation, stagnant USDC supply, margin pressures and regulatory risks.
On Tuesday, Mizuho analyst Dan Dolev initiated coverage on CRCL stock with an Underperform rating and an $85 price target, signaling a potential downside of approximately 60% from current trading levels, which are above $200. 
Read Next: <a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;
Dolev questioned whether the market is overstating Circle&#8217;s medium-term growth prospects, particularly regarding its USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) stablecoin. He argued that current valuations do not properly account for significant risks to future earnings, including increased competition. 
Analysts from JPMorgan and Goldman Sachs previously assigned Circle low price targets of $80 and $83, respectively. 
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/CRCL/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09065842/Screenshot-2025-07-09-at-6.58.34%E2%80%AFAM.png" alt="" class="wp-image-978158" style="box-shadow:var(--wp--preset--shadow--deep);width:920px;height:auto" /></a></figure>
Bullish: On the other hand, some analysts are notably bullish, issuing &#8220;buy&#8221; or &#8220;strong buy&#8221; ratings with price targets ranging from $215 to $250. These analysts have highlighted Circle's growth potential as a stablecoin leader and its expanding market presence.&nbsp;
In late June, Bernstein analysts rated CRCL stock as an Outperform with<a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46165366/circle-stock-is-a-must-hold-says-bernstein-heres-why"> a price target</a> of $230, second only to the Street high price target of $250 issued by Needham.&nbsp;
Bernstein called the stock a "must hold" for investors looking to participate in the evolution of digital dollar networks beyond crypto trading.&nbsp;
The firm's bullish stance is tied to Circle&#8217;s early regulatory advantages under the newly passed GENIUS Act, which establishes a clear framework for stablecoin issuers.
Seaport Global also<a href="https://www.benzinga.com/quote/CRCL/analyst-ratings"> initiated coverage</a> on CRCL with a Buy rating and a $235 price forecast. The firm sees the stablecoin issuer as a top-tier crypto disruptor and well-positioned for substantial future growth.&nbsp;
Wide Range: Meanwhile, other firms, such as Goldman Sachs and Deutsche Bank, take a more neutral or cautious &#8220;hold&#8221; stance, weighing Circle's unique position and warning of elevated valuations. 
Circle's wide range of ratings—from strong buy to sell—and price targets spanning from $80 to $250 show the polarized views on CRCL's future.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46284237/sofi-ready-to-capture-the-opportunity-as-trumps-big-beautiful-plan-restricts-federal-student-loans?utm_source=articleShare">SoFi Ready To &#8216;Capture The Opportunity&#8217; As Trump&#8217;s &#8216;Big, Beautiful&#8217; Plan Restricts Federal Student Loans</a></li>
</ul>
Photo: Shutterstock

Initiation

IPOs

Movers

Tech

Trading Ideas

$USDC

CRCL

The Curious Case Of Circle Stock: Wall Street Can't Agree On The Future Of Finance

Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) has outperformed the market over the past 5 years by 15.03% on an annualized basis producing an average annual return of 29.3%. Currently, Capital One Finl has a market capitalization of $141.31 billion. 
Buying $100 In COF: If an investor had bought $100 of COF stock 5 years ago, it would be worth $356.20 today based on a price of $220.75 for COF at the time of writing.
<h3>Capital One Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752074115_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Capital One Finl Stock In The Last 5 Years

Shares of Evoke Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) are trading sharply higher Wednesday morning after the specialty pharmaceutical company <a href="https://www.benzinga.com/pressreleases/25/07/g46316671/evoke-pharma-receives-notice-of-allowance-for-u-s-patent-application-for-gimoti-extending-orange-b">announced</a> it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its lead product, GIMOTI.
What To Know: The nasal spray is a treatment for adults with moderate to severe symptoms of diabetic gastroparesis. The new patent, which is expected to expire in December 2036, will extend the market exclusivity for GIMOTI&#xAE;, a non-oral formulation of metoclopramide. 
Evoke Pharma plans to list the patent in the FDA&#8217;s Orange Book, a key move in protecting the drug from generic competition. This news sent the company&#8217;s stock price into overdrive, with shares trading significantly higher in Wednesday&#8217;s session.
&#8220;This new patent allowance adds meaningful value to the GIMOTI&#xAE; franchise by reinforcing protection around how and in whom the therapy is used,&#8221; said Matt D&#8217;Onofrio, CEO of Evoke Pharma.
The company stated this patent strengthens GIMOTI&#8217;s position as a critical treatment option for a patient population that often struggles with the effectiveness of traditional pills.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, EVOK shares are trading higher by 171.6% to $7.29 Wednesday morning. The stock has a 52-week high of $12.32 and a 52-week low of $1.94.
Read Also: <a href="https://www.benzinga.com/pressreleases/25/07/g46316671/evoke-pharma-receives-notice-of-allowance-for-u-s-patent-application-for-gimoti-extending-orange-b">Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036</a>
<h2 class="wp-block-heading">How To Buy EVOK Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Evoke Pharma&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

EVOK

Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?

UBS analyst Joshua Spector maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Neutral and lowers the price target from $28 to $26.

UBS Maintains Neutral on Dow, Lowers Price Target to $26

WIIM

COGT

Cogent Biosciences shares are trading higher after the company announced $200 million public offering.

Endeavour Silver shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $7.25 to $8.75.

UBS analyst Joshua Spector maintains Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) with a Buy and lowers the price target from $74 to $73.

UBS Maintains Buy on Ashland, Lowers Price Target to $73

Stoneridge Has Hired Investment Bankers at UBS to Explore Sale, Sources Say

UBS analyst Brian Meredith maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Buy and raises the price target from $78 to $80.

UBS Maintains Buy on WR Berkley, Raises Price Target to $80

PLUG

Plug Power shares are trading higher after the company announced an extension to its hydrogen partnerships through 2030.

UBS analyst Brian Meredith maintains TWFG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWFG#NASDAQ">TWFG</a>) with a Buy and raises the price target from $40 to $42.

TWFG

UBS Maintains Buy on TWFG, Raises Price Target to $42

EVTL

Vertical Aerospace shares are trading lower after the company announced a $60 million public offering.

ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) unveiled an expanded <a href="https://www.benzinga.com/pressreleases/25/07/b46317710/servicenow-teams-up-with-ferrari-hypercar-to-boost-real-time-race-operations" target="_blank" rel="noreferrer noopener">partnership with iconic automotive brand </a><a href="https://www.benzinga.com/pressreleases/25/07/b46317710/servicenow-teams-up-with-ferrari-hypercar-to-boost-real-time-race-operations" target="_blank" rel="noreferrer noopener">Ferrari N.V.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) on Wednesday.
The collaboration enhances Ferrari&#8217;s digital operations, specifically supporting its Hypercar team following a win at the World Endurance Championship.
As the Official Partner, ServiceNow&#8217;s AI-powered platform plays a key role in real-time race execution and operational performance.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46079632/bofa-sees-155-billion-agentic-ai-boom-by-2030-spotlights-microsoft-salesforce-and-others" rel="noreferrer noopener">The Agentic AI Boom Will Be Worth $155 Billion By 2030, Analyst Names Key Beneficiaries</a>
This partnership comes shortly after Guggenheim reiterated a Sell rating on ServiceNow, maintaining a $724 price forecast.
According to&nbsp;<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, NOW stock has gained over 37% in the past year. Investors can gain exposure to the stock via&nbsp;Franklin Exponential Data ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/XDAT#BATS">XDAT</a>).
As the Official Partner, ServiceNow&#8217;s AI-powered platform plays a key role in real-time race execution and operational performance.
Fabio Spoletini, ServiceNow&#8217;s GVP for Southern Europe, Middle East and Africa, emphasized that Ferrari&#8217;s relentless pursuit of excellence mirrors ServiceNow&#8217;s mission to accelerate business transformation.
&#8220;We&#8217;re proud to support their digital transformation, helping them innovate where it counts — on the track, in the factory, and across the business,&#8221; he said.
According to Antonio Torretta, Ferrari&#8217;s Head of IT Strategy and Governance, the platform enables both engineers and business leaders to operate at peak performance.
&#8220;This partnership shows how the right platform can turn pressure into progress—and performance into transformation,&#8221; Torretta said.
The partnership has enabled Ferrari&#8217;s Hypercar team to implement a customized application built on ServiceNow&#8217;s platform.
Launched in late 2024, the solution facilitates streamlined communication, real-time issue tracking, component validation, and stakeholder coordination, meeting the stringent demands of endurance racing.
Beyond the racetrack, ServiceNow powers Ferrari&#8217;s One Digital Portal, which connects more than 25,000 internal and external users globally. This portal centralizes service request management across Ferrari&#8217;s Racing, Sports Car, and Lifestyle divisions, boosting response times and consistency.
The platform also unifies Ferrari&#8217;s IT operations, governance, compliance, and customer service processes.
The collaboration began in 2019 and has grown into a strategic alliance that continues to evolve.
ServiceNow stated that its AI platform enables Ferrari to streamline operations across its 180 global dealerships, spanning over 60 countries.
Price Action: NOW shares are trading higher by 0.02% to $1,023.21 at last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46317315/this-palantir-partnership-uses-ai-and-satellites-to-predict-weather-like-never-before-heres-what-it-means" target="_blank" rel="noreferrer noopener">This Palantir Partnership Uses AI And Satellites To Predict Weather Like Never Before &#8211; Here&#8217;s What It Means</a></li>
</ul>
Photo: Shutterstock

Sports

Markets

General

RACE

XDAT

ServiceNow Helps Ferrari Go Faster With Speed, Data And Precision

UBS analyst Joshua Spector maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Buy and raises the price target from $398 to $410.

UBS Maintains Buy on Sherwin-Williams, Raises Price Target to $410

U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday.
Shares of Verona Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) rose sharply during Wednesday's session after Merck <a href="https://www.benzinga.com/m-a/25/07/46317822/merck-strikes-10-billion-deal-for-verona-secures-first-in-class-copd-drug">announced it will acquire the company in a $10 billion deal.</a>
Merck &amp; Co. agreed on Wednesday to acquire Verona Pharma for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.
Verona Pharma shares jumped 20.6% to $104.81 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Scage Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) jumped 55.4% to $6.53.</li>
<li>ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) gained 47.1% to $5.49, continuing its climb of over 500% during regular trading on Tuesday.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) rose 47% to $1.9200.</li>
<li>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) gained 25.8% to $82.00 after the company announced topline results from its Phase 2 trial for Bivamelagon.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) gained 20.4% to $1.7101. Plug Power announced Wednesday it has renewed and expanded a multi-year hydrogen supply agreement with a longtime U.S.-based industrial gas partner, extending their collaboration through 2030.</li>
<li>The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) rose 16.8% to $12.94 after Bloomberg reported the company is exploring options amid takeover interest.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) gained 15.2% to $27.98 after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $18 to $33.</li>
<li>Precigen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) rose 15.2% to $1.96.</li>
<li>First Majestic Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) jumped 8.1% to $8.64. First Majestic produced 7.9 million AgEq ounces in the second quarter and raised its full-year outlook to 32.6 million on 76% surge in silver and strong gold output.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) gained 7.7% to $9.69.</li>
<li>Metsera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) rose 7.7% to $32.50.</li>
<li>Ligand Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) gained 7.6% to $123.94.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) rose 7.2% to $91.38. Piper Sandler analyst David Westenberg initiated coverage on GeneDx Holdings with an Overweight rating and announced a price target of $110.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/news/25/07/46320283/this-microsoft-analyst-turns-bullish-here-are-top-5-upgrades-for-wednesday">This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday</a></li>
</ul>
Photo via Shutterstock

Intraday Update

GRFS

LGND

MTSR

PGEN

PROK

RYTM

SCAG

VRNA

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday

Press Releases

Heritage Global Inc. Reports Third Quarter 2024 Results

Heritage Global Partners & Cloud Investment Partners to Host Online Auction Featuring Aerospace Defense SATCOM Assets

Heritage Global to Announce Fourth Quarter and Year-End 2024 Results and Host Webcast on Thursday, March 13, 2025

Heritage Global Valuations Strengthens Growth Strategy with the Appointment of Ray Chen to Lead Midwest Business Development Initiatives

Heritage Global Partners to Conduct Major Online Auction of Electriq Power's Assets

Heritage Global Inc. Reports Fourth Quarter and Year-End 2024 Results

Heritage Global Capital Appoints Anastasia Suda Executive Managing Director to Lead Specialty Lending Division

Heritage Global to Announce First Quarter 2025 Results and Host Webcast on Thursday, May 8, 2025

Heritage Global Inc. Reports Profitable First Quarter 2025 Results

Heritage Global to Announce Second Quarter 2025 Results and Host Webcast on Thursday, August 7, 2025

Comments

Heritage Global

Heritage Global (HGBL) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO